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Background. The systemic hemodynamic profile of human
pregnancy is characterized by a decrease in mean arterial pres-
sure, a rise in cardiac output and plasma volume in association
with an increase in renal plasma flow and glomerular filtration
rate. The factors and the time course responsible for the initial
hemodynamic changes seen in human pregnancy have not been
completely documented. We hypothesize that systemic and renal
hemodynamic changes occur early, prior to the presence of the
fetal-placental unit.
Methods. Thirteen women were studied prior to and immedi-
ately following conception in identical fashion at gestational
weeks 6, 8, 10, 12, 24 and 36. Individuals underwent mean arterial
pressure, cardiac output, inulin and PAH clearance determina-
tions.
Results. Mean arterial pressure decreased by six weeks gestation
(mid follicular 81.5 6 2.6 vs. six weeks 68.7 6 2.0 mm tig, P ,
0.001) in association with a significant increase in cardiac output,
a decrease in systemic vascular resistance and an increase in
plasma volume. Renal plasma flow and glomerular filtration rate
increased by six weeks gestation. Plasma renin activity and
aldosterone concentration increased significently by six weeks,
whereas norepinephrine levels did not change throughout preg-
nancy. Atrial natriuretic peptide levels increased later, at 12 weeks
gestation. Plasma cGMP levels decreased and cGMP clearance
increased by six and eight weeks, respectively.
Conclusions. Peripheral vasodilation occurs early in pregnancy
prior to full placentation in association with renal vasodilation and
activation of the renin-angiotensin-aldosterone system. Plasma
volume expansion occurs early, followed later by increases in ANP
concentration, suggesting that ANP increases in response to
changes in intravasular volume.
Normal human pregnancy is characterized by a decrease
in mean arterial pressure accompanied by an increase in
cardiac output and a decrease in systemic vascular resis-
tance [1–3]. The hemodynamic changes found in human
pregnancy have been proposed to be primarily due to
systemic vasodilation [4] similar to other sodium and water
retaining states [5, 6]. These hemodynamic changes have
been documented longitudinally during pregnancy in non-
primate animal species [7–9], in the baboon [10] and in part
in humans [11]. However, the temporal sequence of periph-
eral vasodilation, increased cardiac output and plasma
volume expansion in the initial phases of human pregnancy
remains to be described. Importantly, the magnitude of
these changes is suggested to be maximal in the second
trimester of human pregnancy [3, 12]. The majority of these
observations have been made with women initially studied
after the end of the first trimester and then in the post-
partum period [1–3]. Therefore, it is possible that most if
not all hemodynamic changes occur much earlier in preg-
nancy.
Pseudopregnant rats demonstrate systemic hemody-
namic changes identical to early pregnancy in the absence
of a fetal-placental unit due to the extended function of the
corpora lutea [13]. As well, women demonstrate systemic
hemodynamic changes in the post-ovulatory or luteal phase
of the menstrual cycle qualitatively similar to pregnancy
[14]. These changes are exaggerated during ovarian hyper-
stimulation [15], suggesting that the initial hemodynamic
changes of pregnancy may occur early and not require an
intact maternal-fetal-placental unit.
Increases in glomerular filtration rate, as measured by
creatinine clearance, have been shown to increase as early
as the 6th week of gestation [16–18]. However, more
accurate measurements of glomerular filtration rate, such
as inulin clearance as well as measures of renal plasma flow,
have not been performed at this early stage of human
pregnancy, nor have simultaneous measurements of sys-
temic and renal hemodynamics been performed in human
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pregnancy to determine if the initial peripheral vasodilation
of pregnancy is accompanied by similar changes in renal
hemodynamics.
Activation of the renin-angiotensin-aldosterone system
has been consistently found in human pregnancy [19–21],
where increased and unchanged sympathetic activity [22,
23], and increased, decreased and unchanged atrial natri-
uretic peptide concentrations have been reported [24–27].
Whether changes in these vasopressor systems are directly
related to the peripheral vasodilation of pregnancy has not
been studied longitudinally or extensively in the first tri-
mester of human pregnancy.
Vasodilating substances responsible for the hemody-
namic changes found in human pregnancy have been
sought. Nitric oxide (NO) and its second messenger, cyclic
guanosine 39,59-monophosphate (cGMP), have been shown
to increase in animal pregnancy [28–30]. Moreover, when
inhibitors of NO production such as Nv-nitro-L-arginine
methylester (L-NAME) are given to pregnant rodents, the
hemodynamic changes found in normal pregnancy are
completely reversed [31]. In human pregnancy, much less
information is available concerning NO and its second
messenger cGMP [32–34].
We hypothesize that prior to fully functional placenta-
tion, normal human pregnancy is characterized by primary
systemic and renal vasodilation as well as vasopressor
activation associated with subsequent plasma volume ex-
pansion. The present study was therefore undertaken to
examine systemic and renal hemodynamics, the renin-
angiotensin-aldosterone and sympathetic nervous systems,
as well as plasma volume and atrial natriuretic peptide
levels: (1) in the mid-follicular phase of the menstrual
cycle; (2) immediately after conception; and (3) serially
throughout gestation. The role of NO in the peripheral
vasodilation of pregnancy was also indirectly evaluated in
this study by measuring second messengers of NO including
plasma and urinary cGMP levels.
METHODS
Healthy subjects planning a pregnancy were studied on
the General Clinical Research Center (GCRC) at the
University of Colorado Health Sciences Center between
January 1990 and July 1996. Women were eligible to
participate if they were between the ages of 21 and 40 years,
and did not have a history of hypertension, diabetes
mellitus, or cardiac or renal disease. Women with a previ-
ous history of preeclampsia or pregnancy-induced hyper-
tension were not eligible for study. Women taking oral
contraceptive medications discontinued use at least four
cycles prior to study. After signing informed consent to
procedures approved by the University of Colorado Multi-
ple Institutional Review Board, patients underwent identi-
cal protocols during the mid-follicular phase of the men-
strual cycle and after successful conception. Follicular
phase measurements were obtained between the second
and ninth day after onset of menstruation. After comple-
tion of the non-pregnant studies, subjects contacted the
investigators after successful conception and were studied
at gestational week 6, 8, 10, 12, 24 and 36. All subjects were
asked not to begin vitamin supplementation until after the
12th week of gestation.
Subjects collected a 24-hour urine sample the day prior
to each study. During collection, subjects kept the urine
refrigerated and completed the collection after admission
to the GCRC. Urine samples were immediately processed
and frozen at 270°C until further measurement. Urinary
creatinine and cGMP excretion rates were determined.
Creatinine concentrations were performed to determine
adequate collection. The subjects were admitted to the
GCRC in the morning having ingested only water after
midnight. Following determination of height and weight,
total blood and plasma volumes were determined using a
modified carbon monoxide rebreathing technique previ-
ously described [14, 35]. Seated subjects rebreathed a gas
mixture initially containing 100% O2 in a closed circuit with
a noseclip in place and a CO2-absorber and 5-liter anes-
thesia bag placed in the line to which 100% O2 was added
continuously during the rebreathing procedures. Baseline
blood samples were drawn via an intravenous line in the
antecubital vein after five minutes of rebreathing and 10
and 15 minutes following the addition of 50 ml (ATP)
carbon monoxide to the rebreathing system. Arterial O2
saturation was monitored throughout the rebreathing pro-
cedures and found to remain greater than 95%. Carbon
monoxide concentration was determined in triplicate using
gas chromatography [35]. Total blood volume was calcu-
lated as previously reported [35]. Red cell mass was calcu-
lated as total blood volume multiplied by hematocrit.
Plasma volume was obtained by subtracting red cell mass
from total blood volume.
Patients were then placed in the left lateral decubitus
position in a quiet room for 60 minutes. After thirty
minutes, four blood pressures were determined at five
minute intervals using a sphygmomanometer. The Korot-
koff V sound was used for determining diastolic blood
pressure [36]. Mean arterial pressure was calculated using
the formula: diastolic pressure plus one-third the pulse
pressure. While still in the left lateral decubitus position,
cardiac output (CO) was determined using standard echo-
cardiographic techniques reported by our laboratory and
elsewhere [14, 37, 38]. Systemic vascular resistance (SVR)
was calculated from the formula: SVR 5 MAP 3 80/CO.
Following blood pressure and cardiac output measure-
ments and after an uninterrupted 30 minutes of rest, blood
was withdrawn from an indwelling catheter without a
tourniquet for the determination of serum creatinine and
electrolyte concentrations, serum osmolarity, estradiol,
progesterone, human choriogonadotropin, prolactin, aldo-
sterone concentrations, and plasma norepinephrine, atrial
natriuretic peptide, cGMP and plasma renin activity. Tubes
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used for the collection of plasma renin activity were kept at
room temperature until separated and were immediately
frozen to avoid cryoactivation [21].
With the subjects in the left lateral decubitus position,
inulin (CIn) and para-aminohippurate (CPAH) clearances
were performed to determine glomerular filtration rate and
effective renal plasma flow, respectively [39]. An initial
loading dose of 3.0 gm inulin and 500 mg PAH were given
followed by a constant infusion of 1.5 g inulin/hr and 400
mg PAH/hr. Inulin and PAH were premixed in 5% glucose
in water and infused at a rate of 1 ml/min. Subjects ingested
300 ml water/hr during the study to maintain urine output
above 3 ml/min. One hour after the initial infusion when
steady state levels were achieved, three thirty-minute clear-
ances were performed with the subjects spontaneously
voiding. Blood samples were obtained in the mid-point of
each clearance period for the determination of plasma
inulin and PAH concentrations. Renal blood flow (RBF)
was determined using CPAH divided by one minus the
fraction of hematocrit divided by 100 [RBF 5 CPAH(1 2
Hct/100)]. Renal vascular resistance was calculated as the
ratio between MAP and renal blood flow multiplied by the
constant 79,920 [(MAP/RBF) 3 79,920].
Serum and urinary electrolytes and reproductive hor-
mones were measured by standard laboratory techniques
on the GCRC. Serum and urine creatinine measurements
were performed using the Jaffe´ reaction and a Beckman 2
autoanalyzer. Serum osmolarity was determined by freez-
ing point depression. Serum and urine inulin and PAH
concentrations were determined colorimetrically [40].
Urine and plasma cGMP, serum aldosterone, plasma atrial
natriuretic peptide concentrations and plasma renin activity
(PRA) were determined by radioimmunoassay [41–44].
Samples were thawed once prior to measurement of PRA.
Norepinephrine concentrations were determined radioen-
zymatically [45]. Progesterone, estradiol, prolactin, and
human choriogonadotropin levels were measured by radio-
immunoassay as reported elsewhere [14]. All variables of
the study group were compared using the linear random-
effects model discussed by Laird and Ware [46]. The latter
model is appropriate for repeated measures data, accom-
modates missing values and assesses variability between
subjects as well as variability between multiple observations
on the same subject. The data were modeled by fitting
constants, or first or second order polynomial regression
lines for each variable versus week of gestation, validating
the best-fitting lines with likelihood ratio tests, and super-
imposing the best fit lines on the mean 6 SEM values for
visual inspection and interpretation. The resulting response
curves were compared throughout pregnancy using an
extension of Scheffe’s method for multiple comparisons,
which permits each point along the response curve to be
compared to the value observed during mid-follicular
phase, and the resulting adjusted P value obtained [47]. All
analyses were implemented with SAS Stat and SAS IML
statistical software [48].
RESULTS
Thirteen subjects enrolled in the study and eleven were
successful in becoming pregnant. The demographic charac-
teristics of the women who became pregnant are shown in
Table 1. Subjects were studied on day 5.4 6 0.5 (range 1 to
9) of the follicular phase, week 5.9 6 0.2 (5.0 to 6.7), 8.0 6
0.2 (7.1 to 8.7), 10.0 6 0.3 (8.6 to 11.4), 12.4 6 0.2 (11.6 to
13.6), 24.2 6 0.3 (23.6 to 25.7) and 36.4 6 0.2 (35.7 to 37.6)
of gestation. Three subjects developed complications dur-
ing their pregnancies. One subject, who had a history of two
previous first trimester spontaneous abortions, miscarried
at 8.5 weeks gestation; her data are not included in the data
analysis. A second patient developed asthma at gestational
week 16 and required theophylline and inhaled corticoste-
roid therapy. She was not studied after that point, suffered
no further maternal or fetal complications, and delivered a
full-term healthy baby. Her data are presented and in-
cluded in the data analysis. A third subject developed
preeclampsia with blood pressures greater than 140/90 mm
Hg and 1.2 g/day urinary protein excretion at week 36
gestation. This patient was not studied in the second or
third trimester. Her data are included in the analysis. One
subject had a twin gestation that was uncomplicated. Her
data are included in the data analysis.
Figure 1 demonstrates the systemic hemodynamics
throughout pregnancy. Mean arterial pressure decreased
significantly compared to the mid-follicular phase by week
six gestation. Cardiac output increased as compared to the
mid-follicular phase by the sixth week of gestation with a
simultaneous decrease in systemic vascular resistance. Max-
imum cardiac output occurred in the second and third
trimesters while systemic resistance was at a minimum in
the middle of the first trimester. Plasma and blood volume
increased significantly from the non-pregnant state at six
weeks gestation, reaching maximal levels at week 36 gesta-
tion (Fig. 2). These changes were accompanied by a
significant increase in weight.
Renal plasma flow and glomerular rate filtration in-
creased and renal vascular resistance decreased signifi-
cantly by the first measurement of gestation (Fig. 3).
Table 1. Demographic characteristics of eleven pregnant women
Variable Value
Age years 30.9 6 0.9
Race White:Afro-American 10:1
Nulliparous % 9 (82.5)
Smokers % 1 (8.3)
Family history of preeclampsia 0 (1 unknown)
Time from initial study to conception
months
7.83 6 2.6 (0.8–24.4)
Length of pregnancy weeks 39.0 6 0.5 (36.8–40.7)
Birth weight kg 3.1 6 0.1
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Maximal renal plasma flow and minimal renal vascular
resistance occurred at the eighth week gestation, whereas
the peak glomerular filtration rate occurred in the second
trimester. Filtration fraction decreased significantly by
week six of gestation and remained lower than non-preg-
nant values until the 36th week of pregnancy (data not
shown). Twenty-four-hour urinary creatinine excretion re-
mained unchanged throughout gestation.
Serum electrolyte and hematocrit data are presented in
Table 2. Serum sodium, chloride, total carbon dioxide,
creatinine, blood urea nitrogen concentrations and serum
osmolarity decreased significantly by the first measurement
or the sixth week of gestation. Hematocrit decreased
significantly by week 10 gestation. All values remained
lower than non-pregnant levels for the remainder of preg-
nancy. Reproductive human data are shown in Table 3. All
values were within the expected range for gestational age.
Vasopressor hormone profiles are shown in Figure 4.
Plasma renin activity and plasma aldosterone concentra-
tions increased significantly by the sixth week of gestation.
Plasma aldosterone levels increased further in the third
trimester of pregnancy. Atrial natriuretic peptide concen-
trations increased from non-pregnant values at the 24th
Fig. 1. Systemic hemodynamic changes throughout early human preg-
nancy. Ten women were studied in the mid-follicular phase of the
menstrual cycle and weeks 6, 8, 10, 12, 24, and 36 gestation. Mean arterial
pressure (MAP) decreased and cardiac output (CO) increased signifi-
cantly by week 6 gestation in association with a decrease in systemic
vascular resistance (SVR). *P , 0.05, **P , 0.001.
Fig. 2. Plasma volume (PV), blood volume (BV), and red cell mass
(RCM) determinations in early pregnancy. Ten women were studied in
the mid follicular phase of the menstrual cycle and weeks 6, 8, 10, 12, 24
and 36 gestation. Plasma and blood volume increased significantly by week
6 gestation. Red cell mass remained unchanged throughout pregnancy.
*P , 0.05, **P , 0.0001.
Fig. 3. Renal hemodynamic changes throughout early human pregnancy.
Ten women were studied in the mid-follicular phase of the menstrual cycle
and weeks 6, 8, 10, 12, 24 and 36 gestation. Renal plasma flow and
glomerular filtration rate increased significantly in association with a
decrease in renal vascular resistance by week 6 gestation. Twenty-four-
hour urinary creatinine excretion remained unchanged throughout gesta-
tion. Abbreviations are: CIn, inulin clearance; CPAH, para-aminohippurate
clearance; RVR, renal vascular resistance; UCrV, urinary creatinine
excretion. *P , 0.05, **P , 0.001
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and 36th weeks of gestation. Plasma norepinephrine con-
centrations did not change from the non-pregnant state
throughout pregnancy.
Plasma concentrations of cGMP and cGMP clearance
are shown in Figure 5. Plasma cGMP levels decreased
significantly throughout pregnancy as early as the sixth
week of gestation as compared to the non-pregnant state. A
significant increase in cGMP clearance throughout preg-
nancy was apparent by week six of gestation.
DISCUSSION
This is the first study, to our knowledge, which rigorously
and simultaneously evaluates the initial systemic and renal
hemodynamic and neurohumoral changes of human preg-
nancy. A significant decrease in systemic vascular resistance
associated with an increase in cardiac output resulting in a
decrease in mean arterial pressure prior to placentation
was found. These changes have been shown to occur, but to
a lesser degree, during the menstrual cycle following ovu-
lation in non-pregnant women [14]. Previous studies during
early pregnancy by other investigators have not been as
conclusive for a number of reasons. In the present study,
blood pressure measurements were carefully standardized.
Measurements were performed after one hour in the left
lateral decubitus position in the morning, at the same time
of day under quiet, controlled conditions. The Korotkoff V
sound was used to determine diastolic blood pressure,
which may be more reliable than the Korotkoff IV sound in
pregnancy [34]. Importantly, women were initally studied
prior to conception and immediately after becoming aware
they were pregnant, ensuring early measurements no later
than six weeks gestation [1–3]. During non-pregnant mea-
surements, the phase of the menstrual cycle was also
controlled and performed in the mid-follicular phase, since
hemodynamic changes in the post-ovulatory or luteal phase
of the menstrual cycle are significant [14, 15]. This study
design allowed for the same subjects to be studied longitu-
dinally with appropriate control of many variables known to
affect systemic and renal hemodynamic measurements.
As other investigators have demonstrated, changes in
cardiac output and systemic vascular resistance occurred
early in the first trimester of pregnancy [37, 38]. Differences
across studies in cardiac output measurements have previ-
ously been demonstrated with some showing an increase in
heart rate [37] and others, an increase in stroke volume [38]
accounting for the increased cardiac output found. In this
study, increases in stroke volume in the second and third
trimesters predominated, accounting for the changes in
cardiac output seen (data not shown).
The present findings indicate that complete placentation
is not necessary for the initial hemodynamic changes to
occur in normal human pregnancy. Placentation, which
initially begins between weeks 6 and 8 gestation, is usually
complete by the 12th week [49], well after systemic and
renal hemodynamic changes were observed in the present
study. Therefore, it is likely that maternal factors, possibly
related to changes in ovarian function or extended function
of the corpora lutea, are responsible for the initial periph-
eral vasodilation found in human pregnancy. These obser-
vations are further supported by the changes in systemic
vascular resistance and blood pressure found in pseudo-
pregnant rats [13], in women in the luteal as compared to
the follicular phase of the menstrual cycle [14], as well as
women undergoing ovarian hyperstimulation [15].
Table 2. Serum electrolyte, creatinine, blood urea nitrogen and osmolarity profiles of women undergoing pregnancy
Variable Mid follicular
Weeks gestation
6 8 10 12 24 36
Na mEq/liter 139.5 6 0.5 137.6 6 0.2a 136.3 6 0.4a 136.6 6 0.7a 135.7 6 0.6a 135.6 6 0.6a 137 6 0.5a
Cl mEq/liter 107.3 6 1.2 106.2 6 0.8a 105.0 6 1.5a 105.5 6 0.8a 104.6 6 0.9a 104.9 6 0.6a 106.7 6 1.4a
CO2 mEq/liter 24.7 6 0.4 21.3 6 1.0
a 20.5 6 0.6a 20.5 6 0.9a 20.4 6 0.81a 19.9 6 0.8a 18.9 6 0.9a
K mEq/liter 3.9 6 0.1 4.0 6 0.1 3.7 6 0.1 3.7 6 0.1 3.8 6 0.1 3.7 6 0.1 3.6 6 0.1a
S Osm M Osm/kg 288 6 1.2 277 6 1.4a 276 6 1.6a 275 6 0.8a 275 6 1.0a 274 6 1.4a 275 6 1.7a
BUN mg/dl 11.8 6 1.0 10.4 6 1.0a 9.8 6 1.1a 8.9 6 0.6a 8.6 6 0.5a 8.6 6 0.1a 7.5 6 0.8a
SCr mg/dl 0.8 6 0.1 0.8 6 0.05 0.7 6 0.1
a 0.7 6 0.1a 0.7 6 0.04a 0.6 6 0.04a 0.55 6 0.04a
Hct % 38.7 6 0.8 38.2 6 0.6 38.3 6 0.2 37.2 6 0.9a 37.0 6 0.8a 36.6 6 0.6a 37.0 6 0.8a
Weight kg 61.5 6 2.6 61.0 6 2.9 62.3 6 3.2a 64.4 6 3.0a 64.6 6 2.6a 72.7 6 0.1a 79.2 6 3.2a
a P , 0.05 compared to mid follicular values
Table 3. Reproductive hormones during human pregnancy
Mid-Foll
Weeks gestation
Week 6 Week 8 Week 10 Week 12 Week 24 Week 36
Estradiol pg/ml 54.8 6 8 486.3 6 83 743 6 141 1,004 6 133 1,615 6 173 7,470 6 897 13,894 6 2,122
Progesterone ng/ml 0.21 6 0.03 20.4 6 3.0 30.1 6 6.2 21.4 6 3.9 29.5 6 3.8 166 6 82 224 6 36.6
BHCG mIU 0 10,727 6 4,586 100,038 6 17,973 116,128 6 8,606 78,426 6 12,000 18,953 6 2,954 26,358 6 9,920
Prolactin ng/ml 9.2 6 1.3 29.4 6 10.6 33.1 6 7.3 27.9 6 2.2 36.3 6 4.9 21 6 3.3 145 6 13.5
All pregnancy values significantly greater than mid-follicular, P , 0.001.
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Effective renal plasma flow and glomerular filtration
increased, resulting in decreased renal vascular resistance.
Filtration fraction decreased significantly, indicating a
greater rise in effective renal plasma flow consistent with
primary renal vasodilation. These findings are also found in
the rat model of gestation where initial renal hemodynamic
changes are found early in gestation, between days five and
nine [50]. In contrast to other investigators [16, 17], a
consistent but nonsignificant 6% increase in urinary creat-
inine excretion was found during gestation with no de-
crease found in the third trimester. Although others have
shown a significant and greater (approximately 10%) in-
crease in creatinine excretion during gestation, the fall in
plasma creatinine concentration has always been greater,
accounting for the 45% increase in creatinine clearance
seen during pregnancy [16, 17]. Others have demonstrated
a decrease in urinary creatinine excretion in the third
trimester and followed their subjects weekly, well past the
36th week of gestation [51]. This study therefore may not
have detected significant decreases in urinary creatinine
excretion closer to term.
Other conditions of peripheral vasodilation, such as
sepsis, cirrhosis, and high output congestive heart failure,
result in no change or decreases in renal plasma flow and
increases in renal vascular resistance [5, 6]. This suggests
that the hormonal changes associated with pregnancy have
a specific renal vasodilating effect, overriding secondary
activation of other renal vasoconstricting systems such as
the renin-angiotensin system (RAS). This conclusion is
supported by the relative systemic pressor resistance to
angiotensin II, norepinephrine and vasopressin found in
pregnancy [8, 13].
Fig. 4. Vasopressor hormone profiles throughout early human preg-
nancy. Ten women were studied in the mid-follicular phase of the
menstrual cycle and weeks 6, 8, 10, 12, 24 and 36 gestation. Plasma renin
activity (PRA) and aldosterone (Aldo) levels increased by week 6 gesta-
tion. Norepinephrine (Norepi) concentrations did not change throughout
gestation. Atrial natriuretic peptide (ANP) concentrations increased
significantly by week 12 gestation. **P , 0.001.
Fig. 5. Plasma and clearance values for cGMP, the second messenger for
atrial natriuretic peptide (ANP) and nitric oxide (NO), throughout early
human pregnancy. Ten women were studied in the mid-follicular phase of
the menstrual cycle and weeks 6, 8, 10, 12, 24 and 36 gestation. Plasma
cGMP levels decreased and cGMP clearance increased significantly by
weeks 6 and 8 gestation. respectively. *P , 0.05, **P , 0.001.
Chapman et al: Hemodynamic changes in early human pregnancy 2061
The RAS was activated early as shown by increased PRA
and plasma aldosterone concentrations. In this regard, it is
known that peripheral vasodilation results in activation of
the RAS [19–21]. Although estrogen increases angio-
tensinogen or renin substrate and can activate the RAS
through non-hemodynamic mechanisms [19], PRA and
plasma aldosterone levels are increased during pregnancy
out of proportion to the enhanced substrate availability
[19–21]. Further evidence for the hemodynamic activation
of RAS during pregnancy is that angiotensin converting
enzyme inhibition lowers blood pressure in pregnant
women [52].
In other longitudinal studies of the renin-angiotensin
system in women undergoing normal pregnancy and in vitro
fertilization, PRA were greater than those found in this
study [20, 21]. The change from the non-pregnant state in
PRA and urinary aldosterone excretion in women under-
going ovarian stimulation correlated most closely with
increases in estradiol levels, and were equivalent to a
gestational age of 18 weeks [21]. Why less dramatic changes
were found in the present study is unclear; however, they
may reflect the supine as opposed to the seated position of
the patient, differences in dietary sodium intake, and
differences between assays. In the present study plasma
aldosterone levels continued to rise during the last trimes-
ter independent of a change in PRA, suggesting that factors
other than hemodynamic activation of the RAS, such as
markedly increased progesterone levels, may be important
in the later stages of pregnancy.
Plasma atrial natriuretic peptide levels remained un-
changed during the first trimester as compared to the
non-pregnant state. We and others have previously shown a
decrease in plasma ANP concentrations during the mid-
luteal phase of the menstrual cycle [14, 53]. In the present
study, increases in plasma volume were greater by week six
gestation as compared to the previously reported non-
pregnant mid-luteal phase [14], potentially accounting for
the lack in plasma ANP change in early pregnancy. How-
ever, plasma ANP levels increased 35% by the second
trimester. In previous studies, plasma ANP concentration
has been shown to increase, decrease or not change in the
third trimester of human and rat pregnancy [23–25]. The
present results are similar to a recent meta-analysis of 14
studies where plasma ANP increases significantly in the
later stages of pregnancy in association with increased
plasma volume [25]. These results suggest that plasma ANP
changes found in pregnancy are secondary to increases in
plasma volume, rather than playing a primary role in the
hemodynamic changes found.
Nitric oxide, a potent vasodilator that acts through its
second messenger cGMP, plays an important role in the
systemic and renal hemodynamic changes found in rodent
pregnancy [26–29]. In the present study, cGMP clearance
increased in the setting of decreased plasma cGMP levels,
indicating increased nephrogenous cGMP production.
Most rodent pregnancy studies carefully performed have
demonstrated an increase in both plasma and urinary
excretion of cGMP [27]. However, in human studies,
increased plasma cGMP has not been consistently found
while increases in urinary excretion of cGMP are invariably
present [30–32]. This is similar to the increase in cGMP
clearance found in the present study. These results provide
preliminary evidence that renal production of NO or other
natriuretic substances may account for the increase in
cGMP clearance found.
In summary, peripheral vasodilation occurs early in
pregnancy, prior to fully complete placentation. This vaso-
dilation causes a fall in mean arterial pressure associated
with a rise in cardiac output. Increases in plasma volume
also occur during the same time. Renal vasodilation occurs
simultaneously with the systemic vasodilation as renal
plasma flow and glomerular filtration increase, and renal
vascular resistance and filtration fraction decrease. Activa-
tion of the renin-angiotensin-aldosterone system was found
in association with peripheral vasodilation. Cyclic GMP
clearance increased in the setting of decreased plasma
cGMP levels in the first trimester of pregnancy. Further
studies are needed to confirm and identify the vasodilating
substances responsible for the initial systemic and renal
hemodynamic changes found in early human pregnancy.
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